Tiffany A. LaFortune

1.1k total citations
13 papers, 902 citations indexed

About

Tiffany A. LaFortune is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Tiffany A. LaFortune has authored 13 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Cell Biology. Recurrent topics in Tiffany A. LaFortune's work include PI3K/AKT/mTOR signaling in cancer (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Tiffany A. LaFortune is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Tiffany A. LaFortune collaborates with scholars based in United States, Switzerland and Japan. Tiffany A. LaFortune's co-authors include John de Groot, Dimpy Koul, W.K. Alfred Yung, Ningyi Tiao, W.K. Alfred Yung, Yuji Piao, Vanessa Milano, Sauveur-Michel Maira, Ta-Jen Liu and Ta-Jen Liu and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Tiffany A. LaFortune

13 papers receiving 888 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tiffany A. LaFortune United States	10	592	273	185	161	119	13	902
Satoko Nakada Japan	13	468 0.8×	178 0.7×	153 0.8×	158 1.0×	168 1.4×	38	970
Robert Tressler United States	15	758 1.3×	280 1.0×	198 1.1×	167 1.0×	134 1.1×	20	1.3k
Aizhen Xiao United States	15	393 0.7×	189 0.7×	170 0.9×	253 1.6×	72 0.6×	21	773
Nathan V. Lee United States	14	673 1.1×	459 1.7×	78 0.4×	312 1.9×	150 1.3×	23	1.2k
Alexandra Florin Germany	19	691 1.2×	388 1.4×	73 0.4×	302 1.9×	129 1.1×	27	1.1k
Kristina von Boguslawski Finland	18	527 0.9×	407 1.5×	66 0.4×	240 1.5×	215 1.8×	26	1.1k
Caroline Delmas France	22	794 1.3×	408 1.5×	343 1.9×	433 2.7×	160 1.3×	37	1.4k
Michael De Lay United States	8	546 0.9×	206 0.8×	224 1.2×	387 2.4×	69 0.6×	10	900
Yuanyan Wei China	20	657 1.1×	373 1.4×	79 0.4×	204 1.3×	115 1.0×	35	949
Maria F. Camargo United States	12	586 1.0×	365 1.3×	92 0.5×	212 1.3×	139 1.2×	18	966

Countries citing papers authored by Tiffany A. LaFortune

Since Specialization

Citations

This map shows the geographic impact of Tiffany A. LaFortune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiffany A. LaFortune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiffany A. LaFortune more than expected).

Fields of papers citing papers by Tiffany A. LaFortune

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiffany A. LaFortune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiffany A. LaFortune. The network helps show where Tiffany A. LaFortune may publish in the future.

Co-authorship network of co-authors of Tiffany A. LaFortune

This figure shows the co-authorship network connecting the top 25 collaborators of Tiffany A. LaFortune. A scholar is included among the top collaborators of Tiffany A. LaFortune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiffany A. LaFortune. Tiffany A. LaFortune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Lee, J. Jack, Chandra Bartholomeusz, Hitomi Saso, et al.. (2012). PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis. 1(7). e22–e22. 22 indexed citations

Koul, Dimpy, Jun Fu, Ruijun Shen, et al.. (2011). Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells. Clinical Cancer Research. 18(1). 184–195. 132 indexed citations

Guan, Su, Rulong Shen, Tiffany A. LaFortune, et al.. (2011). Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro-Oncology. 13(7). 748–758. 17 indexed citations

Zhang, Dongwei, Ana M. Tari, Uǧur Akar, et al.. (2010). Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer. Molecular Cancer Therapeutics. 9(11). 3090–3099. 17 indexed citations

Koul, Dimpy, Ruijun Shen, Tiffany A. LaFortune, et al.. (2010). Abstract 350: NVP-BKM120: A selective pan-PI3 kinase inhibitor induces G2/M arrest in glioma cell lines via FOXO3a and GADD45a loop. Cancer Research. 70(8_Supplement). 350–350. 5 indexed citations

Milano, Vanessa, Yuji Piao, Tiffany A. LaFortune, & John de Groot. (2009). Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Molecular Cancer Therapeutics. 8(2). 394–406. 102 indexed citations

Zhang, Dongwei, Tiffany A. LaFortune, Savitri Krishnamurthy, et al.. (2009). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research. 15(21). 6639–6648. 98 indexed citations

LaFortune, Tiffany A., Tiffany A. LaFortune, Peter Ordentlich, et al.. (2009). Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer.. Cancer Research. 69(24_Supplement). 3135–3135. 1 indexed citations

Liu, Ta-Jen, Dimpy Koul, Tiffany A. LaFortune, et al.. (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Molecular Cancer Therapeutics. 8(8). 2204–2210. 203 indexed citations

10.

Yamauchi, Hideko, Tiffany A. LaFortune, & Naoto T. Ueno. (2009). Lapatinib in the Treatment of Breast Cancer. 1. CMT.S52–CMT.S52. 1 indexed citations

11.

Liu, Ta-Jen, Tiffany A. LaFortune, Toshiyuki Honda, et al.. (2007). Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Molecular Cancer Therapeutics. 6(4). 1357–1367. 185 indexed citations

12.

Liu, Juinn-Lin, Tiffany A. LaFortune, Marta M. Alonso, et al.. (2007). Cell Cycle–Dependent Nuclear Export of Phosphatase and Tensin Homologue Tumor Suppressor Is Regulated by the Phosphoinositide-3-Kinase Signaling Cascade. Cancer Research. 67(22). 11054–11063. 44 indexed citations

13.

Koul, Dimpy, Ruijun Shen, Shishir Shishodia, et al.. (2006). Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Molecular Cancer Therapeutics. 5(3). 637–644. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact